IKT

Inhibikase Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website inhibikase.com
Employees(FY) 6
ISIN US45719W2052

Performance

-31.49%

-7.04%

+54.69%

+14.45%

+55.91%

YTD

+130.1%

Profile

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Advanced Technical Analysis

Technical Analysis of IKT 2024-11-20

The stock indicators reflect a predominantly neutral sentiment, with the Moving Average Score at 43, Oscillators Score at 36, and Technical Score at 40, suggesting a cautious outlook as the scores hover around the neutral range, indicating potential indecision in the market. The Oscillators Score, being the weakest at 36, points to bearish press...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of IKT

Stock Rank

Recent News & Updates

2024-11-13 19:37
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity(Globenewswire)
2024-10-22 18:31
Inhibikase Therapeutics Secures Funding and Strengthens Leadership(Yahoo Finance)
2024-10-22 09:07
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc(Yahoo Finance)
2024-10-20 21:05
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension(Globenewswire)
2024-10-17 13:01
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc(Yahoo Finance)
2024-10-11 05:57
Inhibikase Therapeutics Secures $110M for Drug Development(Yahoo Finance)
2024-10-11 01:02
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares(Yahoo Finance)
2024-10-09 20:59
Inhibikase Therapeutics Unveils PAH and Parkinsons Drug Pipeline(Yahoo Finance)
2024-10-08 21:18
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension(Globenewswire)
2024-08-14 04:25
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity(Globenewswire)
2024-08-06 20:00
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024(Globenewswire)
2024-06-16 20:05
Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease(Globenewswire)
2024-06-04 20:05
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs(Globenewswire)
2024-05-19 20:01
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million(Globenewswire)
2024-05-18 20:09
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-15 18:52
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-15 08:00
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity(Globenewswire)
2024-05-14 20:45
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement(Globenewswire)
2024-05-08 20:00
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension(Globenewswire)
2024-04-18 04:30
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs(Globenewswire)
2024-04-02 20:05
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension(Globenewswire)
2024-04-01 22:25
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript(Yahoo Finance)
2024-04-01 22:25
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-28 09:06
Q4 2023 Inhibikase Therapeutics Inc Earnings Call(Yahoo Finance)
2024-03-27 10:53
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-27 04:15
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity(Globenewswire)
2024-03-06 19:30
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders(Globenewswire)
2024-02-28 03:05
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro(Globenewswire)
2024-02-14 20:55
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now(Zacks)
2024-02-06 18:55
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.